NervGen Pharma Corp. (NGEN.V)

CAD 2.46

(-7.17%)

EBITDA Summary of NervGen Pharma Corp.

NervGen Pharma Corp.'s latest annual EBITDA in 2023 was -17.72 Million CAD , up 21.96% from previous year.
NervGen Pharma Corp.'s latest quarterly EBITDA in 2024 Q2 was -13.8 Million CAD , down -20.82% from previous quarter.
NervGen Pharma Corp. reported an annual EBITDA of -20.09 Million CAD in 2022, down -77.08% from previous year.
NervGen Pharma Corp. reported an annual EBITDA of -12.76 Million CAD in 2021, down -15.04% from previous year.
NervGen Pharma Corp. reported a quarterly EBITDA of -13.8 Million CAD for 2024 Q2, down -20.82% from previous quarter.
NervGen Pharma Corp. reported a quarterly EBITDA of -4.6 Million CAD for 2023 Q2, down -1.42% from previous quarter.

Annual EBITDA Chart of NervGen Pharma Corp. (2023 - 2017)

Historical Annual EBITDA of NervGen Pharma Corp. (2023 - 2017)

Year	EBITDA	EBITDA Growth
2023	-17.72 Million CAD	21.96%
2022	-20.09 Million CAD	-77.08%
2021	-12.76 Million CAD	-15.04%
2020	-11.15 Million CAD	-13.44%
2019	-9.82 Million CAD	-634.0%
2018	-1.33 Million CAD	-11232.6%
2017	-11.81 Thousand CAD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-7.45 Million CAD	42.2%
2024 Q2	-13.8 Million CAD	-20.82%
2023 Q2	-4.6 Million CAD	-1.42%
2023 Q1	-4.53 Million CAD	31.89%
2023 FY	- CAD	22.36%
2023 Q4	-4.83 Million CAD	-49.14%
2023 Q3	-3.24 Million CAD	29.54%
2022 Q1	-5.01 Million CAD	-21.59%
2022 FY	- CAD	-77.08%
2022 Q4	-6.66 Million CAD	-38.11%
2022 Q3	-4.82 Million CAD	22.68%
2022 Q2	-6.23 Million CAD	-24.49%
2021 FY	- CAD	-15.04%
2021 Q4	-4.12 Million CAD	-10.89%
2021 Q3	-3.71 Million CAD	-33.43%
2021 Q2	-2.78 Million CAD	-26.73%
2021 Q1	-2.19 Million CAD	48.16%
2020 Q3	-1.95 Million CAD	14.35%
2020 FY	- CAD	-13.44%
2020 Q1	-2.66 Million CAD	7.87%
2020 Q2	-2.28 Million CAD	14.46%
2020 Q4	-4.24 Million CAD	-116.91%
2019 Q4	-2.89 Million CAD	-22.94%
2019 Q2	-1.55 Million CAD	42.13%
2019 Q1	-2.69 Million CAD	-255.4%
2019 Q3	-2.35 Million CAD	-51.03%
2019 FY	- CAD	-634.0%
2018 Q2	-63.66 Thousand CAD	-499.28%
2018 Q3	-506 Thousand CAD	-694.75%
2018 Q4	-758.42 Thousand CAD	-49.89%
2018 FY	- CAD	-11232.6%
2018 Q1	-10.62 Thousand CAD	0.0%
2017 FY	- CAD	0.0%

Peer EBITDA Comparison of NervGen Pharma Corp.

Name	EBITDA	EBITDA Difference
Arch Biopartners Inc.	-430.71 Thousand CAD	-4014.438%
Covalon Technologies Ltd.	-3.49 Million CAD	-407.547%
Hemostemix Inc.	-1.94 Million CAD	-810.78%
Universal Ibogaine Inc.	-4.6 Million CAD	-284.636%
Kane Biotech Inc.	-3.23 Million CAD	-447.91%
MedMira Inc.	-1.57 Million CAD	-1023.586%
Marvel Biosciences Corp.	-2.25 Million CAD	-686.925%
XORTX Therapeutics Inc.	-6.46 Million CAD	-173.963%